SAN FRANCISCO, Nov. 4 /PRNewswire/ -- Jennerex, Inc. (San Francisco, CA and Ottawa, Canada) a clinical-stage biopharmaceutical company, today announced that David H. Kirn, M.D., President and Chief Executive Officer, will present an overview of the Company at the 10th Annual Rodman & Renshaw Healthcare Conference in New York on November 11, 2008 at 3:15 p.m. Eastern Time (12:15 p.m. Pacific Time) at the Palace Hotel, New York.
A webcast of the presentation will be available during the event at http://www.jennerex.com and will be archived and available on the website for 3 months.
Jennerex is a clinical-stage biopharmaceutical company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The company's lead product JX-594, currently in an international Phase 2 trial for primary liver cancer, demonstrated promising Phase 1 efficacy and safety results in patients with a diverse array of common large market cancers. Jennerex's products target, attack and eradicate cancers through a novel and potent oncolytic mechanism that is dependent on highly-specific replication of the company's poxviruses in cancer cells. These products simultaneously stimulate the body's immune response to the cancer. Of note, this mechanism of action and the results in patients to date put the company's product class in a leadership position. Jennerex's position is in marked contrast to gene therapy and standard cancer vaccine approaches. Jennerex Biotherapeutics was established in San Francisco and in Ottawa in 2006 with Dr. David Kirn (CEO) in San Francisco and Dr. John Bell (CSO) from the Ottawa Health Research Institute/University of Ottawa. For more information about Jennerex and the company's robust pipeline and three clinical-stage products, please visit http://www.jennerex.com.
|SOURCE Jennerex, Inc.|
Copyright©2008 PR Newswire.
All rights reserved